82 related articles for article (PubMed ID: 15603898)
1. Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line.
Yang M; Zhu F; Sønderstrup G; Eckels DD
Vaccine; 2005 Jan; 23(7):951-62. PubMed ID: 15603898
[TBL] [Abstract][Full Text] [Related]
2. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
3. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
Kilger E; Pecher G; Schwenk A; Hammerschmidt W
J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
[TBL] [Abstract][Full Text] [Related]
4. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB
Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306
[TBL] [Abstract][Full Text] [Related]
5. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
6. Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background.
Szántó S; Bárdos T; Szabó Z; David CS; Buzás EI; Mikecz K; Glant TT
Arthritis Rheum; 2004 Jun; 50(6):1984-95. PubMed ID: 15188376
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.
Hellebrand E; Mautner J; Reisbach G; Nimmerjahn F; Hallek M; Mocikat R; Hammerschmidt W
Gene Ther; 2006 Jan; 13(2):150-62. PubMed ID: 16136164
[TBL] [Abstract][Full Text] [Related]
8. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals.
Reijonen H; Elliott JF; van Endert P; Nepom G
J Immunol; 1999 Aug; 163(3):1674-81. PubMed ID: 10415074
[TBL] [Abstract][Full Text] [Related]
9. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
10. Transfection of thyroid autoantigens into EBV-transformed B cell lines. Recognition by Graves' disease thyroid T cells.
Mullins RJ; Chernajovsky Y; Dayan C; Londei M; Feldmann M
J Immunol; 1994 Jun; 152(11):5572-80. PubMed ID: 8189073
[TBL] [Abstract][Full Text] [Related]
11. Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses.
Chen Z; de Kauwe AL; Keech C; Wijburg O; Simpfendorfer K; Alexander WS; McCluskey J
Tissue Antigens; 2006 Sep; 68(3):210-9. PubMed ID: 16948641
[TBL] [Abstract][Full Text] [Related]
12. MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide.
Prato S; Maxwell T; Pinzón-Charry A; Schmidt CW; Corradin G; López JA
Eur J Immunol; 2005 Mar; 35(3):681-9. PubMed ID: 15688345
[TBL] [Abstract][Full Text] [Related]
13. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
Chen M; Shirai M; Liu Z; Arichi T; Takahashi H; Nishioka M
J Virol; 1998 Oct; 72(10):8301-8. PubMed ID: 9733874
[TBL] [Abstract][Full Text] [Related]
14. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution.
Holloway PA; Kaldenhoven N; Kok-Schoemaker HM; Dijk Mv; Otten HG; Tilanus M; Postma S; Mutis T; Lokhorst HM; Bloem AC
Br J Haematol; 2005 Jan; 128(1):73-81. PubMed ID: 15606552
[TBL] [Abstract][Full Text] [Related]
15. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.
Chromik J; Schnürer E; Georg Meyer R; Wehler T; Tüting T; Wölfel T; Huber C; Herr W
J Immunol Methods; 2006 Jan; 308(1-2):77-89. PubMed ID: 16336973
[TBL] [Abstract][Full Text] [Related]
16. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
Robson NC; Donachie AM; Mowat AM
Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
[TBL] [Abstract][Full Text] [Related]
18. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
20. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis.
van Sechel AC; Bajramovic JJ; van Stipdonk MJ; Persoon-Deen C; Geutskens SB; van Noort JM
J Immunol; 1999 Jan; 162(1):129-35. PubMed ID: 9886378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
